Collectively, our studies identify a previously unexplored role for FLT1 signaling in driving PARPi resistance in BRCA1/2-mutant breast cancers and suggest that pharmacological inactivation of FLT1 could greatly enhance the efficacy of PARPi treatment in patients. This evidence concerns the gene FLT1 and breast carcinoma.